文献速递冠心病外科

在真实世界的外科治疗缺血性心力衰竭试验人群中比较冠状动脉旁路移植术与经皮冠状动脉介入治疗的效果

Comparative effectiveness of coronary artery bypass grafting versus percutaneous coronary intervention in a real-world Surgical Treatment for Ischemic Heart Failure trial population.
PubMed 文献 · J Thorac Cardiovasc Surg · 2018-06-01

本研究为多中心回顾性分析,纳入2004至2014年间7个医疗中心中符合外科治疗缺血性心力衰竭试验标准的955例冠状动脉旁路移植术和718例经皮冠状动脉介入治疗患者,其射血分数≤35%且为2支或3支血管病变。经风险调整后,冠状动脉旁路移植术与经皮冠状动脉介入治疗相比与长期生存改善相关(风险比0.59;95%置信区间0.50-0.71;P<.01)。作者认为对于缺血性心肌病和多支冠状动脉病变患者应强烈考虑冠状动脉旁路移植术。

要点

  • 在射血分数≤35%且多支血管病变患者中,冠状动脉旁路移植术较经皮冠状动脉介入治疗与长期生存改善相关(风险比0.59;95%置信区间0.50-0.71;P<.01)。
  • 两种血运重建方式的30天死亡率相似(P=.14)。
  • 冠状动脉旁路移植术与较高的卒中和急性肾损伤频率相关,而经皮冠状动脉介入治疗与较高的再次血运重建发生率相关(均P<.001)。

核心结论

  • 在射血分数降低且多支血管病变的患者中,冠状动脉旁路移植术较经皮冠状动脉介入治疗与长期生存改善相关。
  • 作者建议对缺血性心肌病和多支冠状动脉病变患者强烈考虑冠状动脉旁路移植术。

研究设计与样本

  • 多中心回顾性分析,纳入2004至2014年间7个医疗中心向北部新英格兰心血管疾病研究组报告的所有冠状动脉旁路移植术(n=18,292)和经皮冠状动脉介入治疗(n=55,438)。
  • 应用外科治疗缺血性心力衰竭试验的纳入和排除标准后,纳入射血分数≤35%且为2支或3支血管病变的955例冠状动脉旁路移植术和718例经皮冠状动脉介入治疗患者。
  • 使用逆概率加权进行风险调整,主要终点为全因死亡率,次要终点包括30天死亡率、卒中、急性肾损伤和再次血运重建发生率。

主要发现

  • 中位随访时间为4.3年(范围1.59-6.71年)。
  • 经风险调整后,冠状动脉旁路移植术较经皮冠状动脉介入治疗与长期生存改善相关(风险比0.59;95%置信区间0.50-0.71;P<.01)。
  • 冠状动脉旁路移植术与经皮冠状动脉介入治疗的30天死亡率相似(P=.14)。
  • 冠状动脉旁路移植术与较高的卒中频率相关(P<.001),也与较高的急性肾损伤频率相关(P<.001)。
  • 经皮冠状动脉介入治疗与较高的再次血运重建发生率相关(P<.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: There are no prospective randomized trial data to guide decisions on optimal revascularization strategies for patients with multivessel coronary artery disease and reduced ejection fraction. In this analysis, we describe the comparative effectiveness of coronary artery bypass grafting (CABG) versus percutaneous coronary intervention (PCI) in this patient population. METHODS: A multicenter, retrospective analysis of all CABG (n = 18,292) and PCIs (n = 55,438) performed from 2004 to 2014 among 7 medical centers reporting to the Northern New England Cardiovascular Disease Study Group. After applying inclusion and exclusion criteria from the Surgical Treatment for Ischemic Heart Failure trial, there were 955 CABG and 718 PCI patients with an ejection fraction ≤ 35% and 2- or 3-vessel disease. Inverse probability weighting was used for risk adjustment. The primary end point was all-cause mortality. Secondary end points included rates of 30-day mortality, stroke, acute kidney injury, and incidence of repeat revascularization. RESULTS: The median duration of follow-up was 4.3 years (range, 1.59-6.71 years). CABG was associated with improved long-term survival compared with PCI after risk adjustment (hazard ratio, 0.59; 95% confidence interval, 0.50-0.71; P < .01). Although CABG and PCI had similar 30-day mortality rates (P = .14), CABG was associated with a higher frequency of stroke (P < .001) and acute kidney injury (P < .001), whereas PCI was associated with a higher incidence of repeat revascularization (P < .001). CONCLUSIONS: Among patients with reduced ejection fraction and multivessel disease, CABG was associated with improved long-term survival compared with PCI. CABG should be strongly considered in patients with ischemic cardiomyopathy and multivessel coronary disease.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Iribarne A, DiScipio AW, Leavitt BJ, et al. Comparative effectiveness of coronary artery bypass grafting versus percutaneous coronary intervention in a real-world Surgical Treatment for Ischemic Heart Failure trial population. J Thorac Cardiovasc Surg. 2018. PMID: 29961592. doi:10.1016/j.jtcvs.2018.04.121

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。